Comment on the article by Durmus et al. “Clinical significance of MEFV mutations in ankylosing spondylitis”

2010 ◽  
Vol 77 (3) ◽  
pp. 281 ◽  
Author(s):  
Nurullah Akkoc ◽  
Ahmet Gul
2009 ◽  
Vol 76 (3) ◽  
pp. 260-264 ◽  
Author(s):  
Dilek Durmus ◽  
Gamze Alayli ◽  
Kivanc Cengiz ◽  
Serbulent Yigit ◽  
Ferhan Canturk ◽  
...  

2017 ◽  
Vol 37 (3) ◽  
pp. 639-646 ◽  
Author(s):  
Renfang Han ◽  
Xiao Yang ◽  
Mengya Chen ◽  
Xu Zhang ◽  
Yaping Yuan ◽  
...  

2007 ◽  
Vol 44 (1-3) ◽  
pp. 265-266
Author(s):  
Zai-xing Yang ◽  
Yan Liang ◽  
Xian-ming Zeng ◽  
Yan Wang ◽  
Ling-zhen Zhang ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1641.2-1641
Author(s):  
Y. Huang ◽  
M. Liu ◽  
Q. Huang ◽  
T. W. Li

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the sacroiliac joints and spine. Lipid profiles, including total cholesterol(TC), high-density lipoprotein cholesterol(HDL-c), low-density lipoprotein cholesterol (LDL-c), TC/HDL-c, triglycerides(TG), have been reported to be changed regularly in axSpA patients. However, the clinical significance of lipid profiles in axSpA patients is controversial.Objectives:The study aims to determine the clinical significance of TC, HDL-c, LDL-c, TC/HDL-c, TG for axSpA patients.Methods:A total of 208 axSpA patients and 113 healthy subjects were enrolled in the study retrospectively. TC, HDL-c, LDL-c, TC/HDL-c, TG, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index(BASDAI) were collected. AxSpA patients were divided into remission axSpA group(BASDAI<4, n=123) and active axSpA group(BASDAI≥4, n=85). Relationships between the parameters were assessed by the Sperman’ s correlations analysis. Receiver operation characteristic (ROC) curves were used to discriminate axSpA patients from healthy subjects and active axSpA group from remission axSpA group.Results:TC, HDL-c, and TG in axSpA group were lower than those of control group, while TC/HDL-c was higher (P<0.05). ROC curve results showed that the AUC value of HDL-c for axSpA was 0.790 (CI95%: 0.740-0.839), yielding a highest AUC value. The optimal cutoff value of HDL-c for axSpA was 1.095, with the Youden index of 0.496, sensitivity of 65.5% and specificity of 84.1%. HDL-c was negatively correlated with BASDAI (r=-0.159, P=0.022). TC/HDL-c was positively correlated with BASDAI (r=0.183, P=0.008). Besides, TC/HDL-c, CRP, ESR in active axSpA group were higher than those of remission axSpA group, while HDL-c was lower (P<0.05). ROC curve results showed that the AUC value of TC/HDL-c and CRP for active axSpA group were 0.621 (CI95%: 0.543-0.700) and 0.634 (CI95%: 0.556-0.712), yielding a higher AUC value than other parameters. The optimal cutoff value of TC/HDL-c for active axSpA group was 4.429, with the Youden index of 0.201, sensitivity of 40.2% and specificity of 79.9%.Conclusion:HDL-c was decreased in axSpA patients with a highest diagnostic value, compared with healthy control. TC/HDL-c was elevated in active axSpA patients, showing a significant correlation to the disease activity of axSpA.References:[1]Gluszko P, Bonek K, Rupinski R, et al. LIPID PROFILE AND ACTIVE SYSTEMIC INFLAMMATION MAY DIFFERENTLY AFFECT THE PATHOMECHANISM OF CARDIOVASCULAR DISORDERS IN ANKYLOSING SPONDYLITIS (AS) AND IN PSORIATIC ARTHRITIS (PSA)[J]. ANNALS OF THE RHEUMATIC DISEASES. 2016: 1146.Acknowledgments:This study was supported by Science and Technology Project of Guangzhou Haizhu District (Haike Business Infox 2018-89).Disclosure of Interests:None declared


2022 ◽  
Vol 42 (2) ◽  
pp. 293-295
Author(s):  
Sang-Hyon Kim ◽  
Ji-Hyun Lee ◽  
Hye-Jin Jeong ◽  
Ji-Min Kim ◽  
Won-Ki Baek ◽  
...  

Author(s):  
Ayşe Ünal Enginar ◽  
Mustafa Gündoğdu

Abstract Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterised by pain, inflamed nodules, abscess, sinus tract, and fistula. HS is more common in patients with axial spondyloarthritis (SpA) and Familial Mediterranean Fever (FMF) compared to the normal population. Mediterranean fever gene (MEFV) mutations are thought to be responsible for the relationship between these three diseases. Case reports of secukinumab treatment in HS have been reported. In this article, a case of successful treatment of HS with secukinumab in a patient with ankylosing spondylitis (AS) and FMF is presented.


Sign in / Sign up

Export Citation Format

Share Document